Ivermectin

"Randomized Control Trials" subset of all papers mentioned

https://c19ivm.org/chowdhury.html

• A Comparative Study on Ivermectin-Doxycycline and Hydroxychloroquine-Azithromycin Therapy on COVID-19 Patients
  • Chowdhury et al., Eurasian Journal of Medicine and Oncology, doi:10.14744/ejmo.2021.16263

  • Comments Not double blind, Ivermectin combined with Doxycyline versus Hydroxychloroquine with Azithromycin, hence comparing two combinations

  • not Ivermectin only versus placebo, nor Ivermectin+X versus X alone

https://c19ivm.org/mahmud.html

• Ivermectin in combination with doxycycline for treating COVID-19 symptoms: a randomized trial
  • Mahmud et al., Journal of International Medical Research, doi:10.5061/dryad.qjq2bvqf6

  • Comments Better designed, Double-blind combination test, 3 deaths in doxy-only control group. This is promising, but 3 deaths is NOT enough to make the p=0.25 claim

https://c19ivm.org/ahmed.html

• A five day course of ivermectin for the treatment of COVID-19 may reduce the duration of illness
  • Ahmed et al., International Journal of Infectious Diseases, doi:10.1016/j.ijid.2020.11.191

  • Comments Not double blind, PCR testing started late so "time to" tests seem subjective

https://c19ivm.org/chaccour.html

• The effect of early treatment with ivermectin on viral load, symptoms and humoral response in patients with non-severe COVID-19: A pilot, double-blind, placebo-controlled, randomized clinical trial
  • Chaccour et al., EClinicalMedicine, doi:10.1016/j.eclinm.2020.100720
  • 12 patients in each treatment wing, too small to make valid conclusions

https://c19ivm.org/babalola.html

• Ivermectin shows clinical benefits in mild to moderate COVID19: A randomised controlled double-blind, dose-response study in Lagos
  • Babalola et al., QJM: An International Journal of Medicine, doi:10.1093/qjmed/hcab035
  • 20 patients in each treatment wing, too small to make valid conclusions

https://c19ivm.org/ravikirti.html

• Ivermectin as a potential treatment for mild to moderate COVID-19: A double blind randomized placebo-controlled trial

  • Ravikirti et al., Journal of Pharmacy & Pharmaceutical Sciences, doi:10.18433/jpps32105

  • 55 / 57 patients in each treatment wing, more than most

https://c19ivm.org/bukhari.html

• Efficacy of Ivermectin in COVID-19 Patients with Mild to Moderate Disease
  • Bukhari et al., medRxiv, doi:10.1101/2021.02.02.21250840
  • 41 / 45 patients in each treatment wing

https://c19ivm.org/mohan.html

• Single-dose oral ivermectin in mild and moderate COVID-19 (RIVET-COV): a single-centre randomized, placebo-controlled trial
  • Mohan et al., Journal of Infection and Chemotherapy, doi:10.1016/j.jiac.2021.08.021

https://c19ivm.org/biber.html

https://c19ivm.org/lopezmedina.html

https://c19ivm.org/chahla.html

• 87%

https://c19ivm.org/faisal.html

• 68%

https://c19ivm.org/aref.html

• 63%

https://c19ivm.org/krolewiecki.html

• -152%

https://c19ivm.org/vallejos2.html

• -33%

https://c19ivm.org/togetherivm.html

• 43%
• Effect of Early Treatment with Ivermectin among Patients with Covid-19
  • Reis et al., New England Journal of Medicine, doi:10.1056/NEJMoa2115869

• 84 negative issues, 36 critical, 23 serious, 21 major SERIOUS BULLSHIT PROBLEM

https://c19ivm.org/buonfrate.html

• -211%

https://c19ivm.org/abbas2.html

• -4%

https://c19ivm.org/manomaipiboon.html

• 43%

https://c19ivm.org/delarocha.html

• -187%

https://c19ivm.org/rezai3.html

• -5%

https://c19ivm.org/mirahmadizadeh.html

• 67%

https://c19ivm.org/schilling.html

• 67%

https://c19ivm.org/covidoutivm.html

• -197%